Search

Search Constraints

You searched for: Author/Creator Arnason, Jon

Search Results

2. 925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy. (4th December 2021)

3. 925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy. (4th December 2021)

4. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. (20th January 2017)

5. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Issue 10343 (18th June 2022)

7. Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy. (27th July 2022)

10. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Issue 10254 (19th September 2020)